Accruing preclinical evidence about metabotropic glutamate 5 receptor antagonists as treatments for drug dependence highlights the irreplaceable contributions of animal studies to the discovery of new medications for human disorders

Neuropsychopharmacology

Volumn 34, Issue 4, 2009, Pages 817-819

  Markou, Athina ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; METABOTROPIC RECEPTOR ANTAGONIST; METHAMPHETAMINE;

COGNITIVE THERAPY; DRUG ABUSE; DRUG DEPENDENCE; HUMAN; NONHUMAN; NOTE; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; TOBACCO DEPENDENCE;

ANIMAL EXPERIMENTATION; ANIMALS; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MICE; MICE, MUTANT STRAINS; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; SUBSTANCE-RELATED DISORDERS;

EID: 59949101215     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.218     Document Type: Note

References (9)

1. Chiamulera C, Epping-Jordan MP, Zocchi A, Marcon C, Cottiny C, Tacconi S et al (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 4: 873-874.
2. Chojnacka-Wójcik E, Palucha A, Gasparini F, Kuhn R et al (2001). Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 132: 1423-1430.
3. Gass JT, Osborne MP, Watson NL, Brown JL, Olive MF (2009). mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology In press.
4. Kalivas PW, Volkow ND (2005). The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 162: 1403-1413.
5. Kuhn TS (1996). The Structure of Scientific Revolutions. University of Chicago Press: Chicago.
6. Liechti ME, Markou A (2008). Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 22: 705-724.
7. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology In press.
8. Morgenstern J, McKay JR (2007). Rethinking the paradigms that inform behavioral treatment research for substance use disorders. Addiction 102: 1377-1389.
9. Substance Abuse and Mental Health Services Administration (2008). Results from the 2007 National Survey on Drug Use and Health: National Findings (Office of Applied Statistics, NSDUH Series H-34, DHHS Publication No. SMA 08-4343). Substance Abuse and Mental Health Services Administration: Rockville.